Sio Gene Therapies' litany of clinical disappointments over the last few years has finally led to the demise of the biotech, formerly known as Axovant and one of the 'vant' companies origin
Axovant has said it plans to continue developing its Parkinson’s Disease gene therapy after reporting supportive data from a small cohort of patients from a phase 2 trial.
Swiss biotech Axovant started the year badly, dropping its Alzheimer’s drug intepirdine after it failed in a trial, and it has ended with another flop from a neuroscience drug, nelotanserin
Last month the biotech Axovant was rocked by the failure of its star drug intepirdine in Alzheimer’s disease – and the fall-out is still being felt, with CEO David Hung deciding to walk out.